The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with diabetic retinopathy who have previously responded to at least 2 intravitreal ...

Cataracts are a common reason for blurry vision, especially as we age. But eye experts say other serious conditions like ...

W. L. Gore & Associates, Inc. ("Gore"), a global materials science company, recently announced the commercial launch of the 0 ...

Sunir Garg, MD, discusses a challenge in ophthalmological procedures: patient discomfort during intravitreal injections ...

The new offering, designed specifically for prefilled syringes used in various applications, complements its 1 mL ImProject ...

Retinitis Pigmentosa therapies evolve beyond gene-specific fixes with gene-agnostic, intravitreal, and optogenetic advances ...

Susvimo is the first and only FDA-approved, continuous delivery treatment shown to maintain vision in people with DR with ...

Diabetic retinopathy affects almost 10 million people in the US and is the third FDA-approved indication for Susvimo, which is also approved for treating neovascular or ‘wet’ age-related macular ...

LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK) ...